^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ASP7517
i
Other names: ASP7517, ASP 7517
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Astellas, Riken
Drug class:
NK cell stimulant, Wilms tumor 1 inhibitor
Related drugs:
4ms
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=24, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
Keytruda (pembrolizumab) • ASP7517
9ms
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=24, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2027 --> Jun 2024 | Trial primary completion date: Dec 2027 --> Jun 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
over1year
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
P1/2, N=43, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
Trial completion • Trial completion date • Trial primary completion date
|
ASP7517
over1year
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=24, Active, not recruiting, Astellas Pharma Global Development, Inc. | N=385 --> 24
Enrollment change • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
almost2years
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=385, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
almost3years
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=385, Recruiting, Astellas Pharma Global Development, Inc. | Initiation date: Jul 2021 --> Dec 2021
Trial initiation date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
3years
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=385, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
over3years
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
P1/2, N=385, Not yet recruiting, Astellas Pharma Global Development, Inc.
Clinical • New P1/2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
Share via
